Guggenheim Maintains Buy on Compass Therapeutics, Lowers Price Target to $4

Benzinga · 3d ago
Guggenheim analyst Michael Schmidt maintains Compass Therapeutics (NASDAQ:CMPX) with a Buy and lowers the price target from $8 to $4.